-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 19, Sansheng Guojian announced that the company's new recombinant humanized anti-IL-1β humanized monoclonal antibody injection (SSGJ-613) has completed the first phase I clinical study in healthy subjects
This study is a phase I clinical study evaluating the safety, tolerability and pharmacokinetic characteristics of a randomized, double-blind, placebo-controlled single subcutaneous injection of SSGJ-613 in healthy subjects
IL-1β belongs to the IL-1 family
Note: The original text has been deleted